Table 6.
The data for HIV virus detection tests for samples from Seroconversion panels PRB956, PRB958 and PRB 973
| Panel no. | Member no. | Days since first bleed | Fiebig stage*** [3] | HIV RNA* (x103, copies/ml) | Signal-to-cut-off ratio | ||
|---|---|---|---|---|---|---|---|
| Other commercial tests* | Present study | ||||||
| PE HIV p24 HM-ELISA | PE HIV p24 HM-ELISA+PSAM | ||||||
| PRB956 | PRB956-01 | 0 | I | BLD** | <1 (0.3) | 0.26 | 0.52 |
| PRB956-02 | 40 | I | 0.71–0.84 | <1 (0.3–0.4) | 0.25 | 0.59 | |
| PRB956-03 | 42 | I | 3.2–9.1 | <1 (0.3–0.4) | 0.28 | 1.05 | |
| PRB956-04 | 47 | II | 63–230 | <1 (0.3–0.4) | 1.15 | 2.41 | |
| PRB956-05 | 50 | III | 60–570 | >1 (3.5–20.2) | 2.84 | 3.04 | |
| PRB958 | PRB958-01 | 0 | I | BLD**-0.43 | <1 (0.3–0.6) | 0.25 | 0.38 |
| PRB958-02 | 2 | I | 1–3.1 | <1 (0.3–0.4) | 0.24 | 0.29 | |
| PRB958-03 | 7 | I | 100–290 | (0.8–5.4) | 0.86 | 2.62 | |
| PRB958-04 | 9 | II | 300–700 | >1 (2.1–17.8) | 1.86 | 3.27 | |
| PRB958-05 | 15 | III | 40–1600 | >1 (2.9–19.8) | 3.01 | 3.52 | |
| PRB958-06 | 17 | III | 470–1200 | >1 (3.3–21.5) | 2.93 | 3.47 | |
| PRB973 | PRB973-01 | 0 | I | 0.68–2.7 | <1 | 0.28 | 0.73 |
| PRB973-02 | 2 | I | 6.4–28 | <1 | 0.33 | 1.05 | |
| PRB973-03 | 7 | II | 91–220 | >1 | 1.20 | 3.98 | |
| PRB973-04 | 11 | III/IV | 500–2200 | >1 | 4.64 | 5.42 | |
*
As determined recently by various methods (insert information);
**
BLD = below the limit of detection;
***
Fiebig stages for HIV detection in blood: stage I: only RNA assay positive; stage II: RNA and HIV-1 p24 antigen tests positive, antibody EIA non-reactive; stage III: RNA, HIV-1 antigen and HIV IgM-sensitive EIA reactive, but Western blot without HIV-1-specific bands; stage IV: as stage III, but indeterminate Western blot pattern; stage V: as stage IV, but reactive Western blot pattern, without p31 (pol) reactivity; stage VI: as stage V, but full Western blot reactivity.